Further study demonstrated that HOXA13 partly promoted glioma progression through epithelial-mesenchymal transition induced by the Wnt and TGF-β pathways; this is known as a potential biomarker of GBM and an independent risk factor for prognosis in patients with advanced glioma [29]. Here, HOXA13 is linked to central nervous system cancer.